ATAI Life Sciences AG 4
4 · IntelGenx Technologies Corp. · Filed Sep 5, 2023
Insider Transaction Report
Form 4
ATAI Life Sciences B.V.
10% Owner
Transactions
- Purchase
Convertible Promissory Note
2023-08-31(indirect: By ATAI Life Sciences AG)Exercise: $0.18Exp: 2026-08-31→ Common Stock (12,000,000 underlying) - Purchase
Warrant (Right to Buy)
2023-08-31+11,999,100→ 11,999,100 total(indirect: By ATAI Life Sciences AG)Exercise: $0.26Exp: 2026-08-31→ Common Stock (11,999,100 underlying)
Footnotes (3)
- [F1]Each of the convertible promissory notes and the warrants are convertible and exercisable, respectively, at the option of the holder, subject to the shareholder approval limitations, as described further in the respective documents.
- [F2]On August 31, 2023, ATAI Life Sciences AG purchased 2,220 units from the Issuer, with each unit consisting of (i) $1,000 principal amount convertible promissory note and (ii) 5,405 warrants to purchase shares of Common Stock, for aggregate consideration of $2,220,000.
- [F3]Reflects securities held of record by ATAI Life Sciences AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein.